Autolus Therapeutics plc
AUTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $10 | $2 | $6 | $2 |
| % Growth | 496% | -72.6% | 311% | – |
| Cost of Goods Sold | $141 | $0 | $0 | $0 |
| Gross Profit | -$131 | $2 | $6 | $2 |
| % Margin | -1,293.5% | 100% | 100% | 100% |
| R&D Expenses | $158 | $130 | $117 | $111 |
| G&A Expenses | $0 | $47 | $32 | $32 |
| SG&A Expenses | $0 | $47 | $32 | $32 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$48 | $4 | -$0 | -$1 |
| Operating Expenses | $111 | $181 | $149 | $142 |
| Operating Income | -$241 | -$180 | -$143 | -$140 |
| % Margin | -2,385.6% | -10,583.1% | -2,307% | -9,314.8% |
| Other Income/Exp. Net | $22 | -$29 | -$6 | -$2 |
| Pre-Tax Income | -$219 | -$208 | -$149 | -$142 |
| Tax Expense | $2 | -$0 | $0 | $0 |
| Net Income | -$221 | -$208 | -$149 | -$142 |
| % Margin | -2,180.5% | -12,272.3% | -2,403% | -9,429.1% |
| EPS | -0.87 | -1.2 | -1.57 | -1.97 |
| % Growth | 27.5% | 23.6% | 20.3% | – |
| EPS Diluted | -0.87 | -1.2 | -1.57 | -1.97 |
| Weighted Avg Shares Out | 255 | 174 | 95 | 72 |
| Weighted Avg Shares Out Dil | 255 | 174 | 95 | 72 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $14 | $2 | $0 |
| Interest Expense | $9 | $45 | $9 | $1 |
| Depreciation & Amortization | $8 | $7 | $7 | $8 |
| EBITDA | -$233 | -$157 | -$132 | -$132 |
| % Margin | -2,303.1% | -9,232.6% | -2,135% | -8,790.6% |